I agree on your assessment of 100X on UK NHS universal healthcare reimbursement to patients prescribed ActiPatch for pain management by their Physicians. Population and number of users much less than U.S., HOWEVER, is this still not huge?
When BIEL receives further FDA OTC Clearances for back and general pain, which it will, BIEL will then work to trigger retail deals, perhaps already made conditional upon those additional clearances or work toward making large chain retail deals.
So, compare the two scenarios. The NHS in the UK will benefit by not having to reimburse the much more expensive drugs it is now; no side-effects as now; less NHS reimbursement for hospital and Physician visits, safer, healthier patients..... in my opinion, NHS will be urging the prescribing of ActiPatch and saving an extraordinary amount of money it is paying out now. And BIEL will benefit quickly as pipelines of inventory fill.
My speculation was always that FDA OTC general clearance would happen first, with NHS UK Tariff reimbursement following, never dreaming FDA would not logically see that it’s OTC clearance for foot and knee would embarrass them if they did not make it general clearance simultaneously......that’s on them. I could be kind and say it’s a junior oversight error by a newbie because anything else defies logic - dem bones is aaaall connected, but time marches on, while many folks concerned about pain drugs are shaking their heads in wonderment.....saying, hmmm, now that’s curious - drug-free, efficacious and safe and FDA has partially but not fully OTC cleared? Why not?
On balance, I prefer NHS UK reimbursement first as it’s a faster launch with quicker profitability than the U.S. So Jimzin, I stick with my earlier price speculations, just reverse the country clearances -UK now fully OTC cleared and NHS Rx reimbursement, so Physician patient users pay nothing! I like where we are!
